Citation Impact
Citing Papers
Permissive Secondary Mutations Enable the Evolution of Influenza Oseltamivir Resistance
2010 ScienceNobel
T-705 (Favipiravir) Induces Lethal Mutagenesis in Influenza A H1N1 Viruses In Vitro
2013
Immunomodulatory Function of Interleukin 28B During Primary Infection With Cytomegalovirus
2014 StandoutNobel
Cytomegalovirus Replication Kinetics in Solid Organ Transplant Recipients Managed by Preemptive Therapy
2012
Bacterial glycosyltransferase-mediated cell-surface chemoenzymatic glycan modification
2019 StandoutNobel
Pretransplant Immediately Early-1-Specific T Cell Responses Provide Protection for CMV Infection After Kidney Transplantation
2013
Virulence determinants of pandemic influenza viruses
2011
Messenger RNA-Based Vaccines Against Infectious Diseases
2020 StandoutNobel
A Direct and Indirect Comparison Meta-Analysis on the Efficacy of Cytomegalovirus Preventive Strategies in Solid Organ Transplant
2014
Impact of a Preemptive Strategy After 3 Months of Valganciclovir Cytomegalovirus Prophylaxis in Kidney Transplant Recipients
2010
Incidence of cytomegalovirus UL97 and UL54 amino acid substitutions detected after 100 or 200 days of valganciclovir prophylaxis
2012
A population-dynamic model for evaluating the potential spread of drug-resistant influenza virus infections during community-based use of antivirals
2003
Infectious Diseases Society of America/American Thoracic Society Consensus Guidelines on the Management of Community-Acquired Pneumonia in Adults
2007 Standout
Syndemics and the biosocial conception of health
2017 Standout
Influenza neuraminidase: A druggable target for natural products
2011
Updated International Consensus Guidelines on the Management of Cytomegalovirus in Solid-Organ Transplantation
2013
Randomized Controlled Trials to Define Viral Load Thresholds for Cytomegalovirus Pre-Emptive Therapy
2016
Fatal outcome of human influenza A (H5N1) is associated with high viral load and hypercytokinemia
2006 Standout
Dynamics of cell‐mediated immune responses to cytomegalovirus in pediatric transplantation recipients
2011
Assessment of Cytomegalovirus-Specific Cell-Mediated Immunity for the Prediction of Cytomegalovirus Disease in High-Risk Solid-Organ Transplant Recipients: A Multicenter Cohort Study
2012
Efficacy of Extended Valganciclovir Prophylaxis in Preventing Cytomegalovirus Infection in Pediatric Kidney Transplantation
2014
Use of Leflunomide in Renal Transplant Recipients with Ganciclovir-Resistant/Refractory Cytomegalovirus Infection: A Case Series from the University of Chicago
2015
Predominant Role of Bacterial Pneumonia as a Cause of Death in Pandemic Influenza: Implications for Pandemic Influenza Preparedness
2008 Standout
Lethal Mutagenesis of Hepatitis C Virus Induced by Favipiravir
2016 StandoutNobel
Resistant influenza A viruses in children treated with oseltamivir: descriptive study
2004
Strategies for containing an emerging influenza pandemic in Southeast Asia
2005 StandoutNature
Treatment of epidemic and pandemic influenza with neuraminidase and M2 proton channel inhibitors
2003
Influenza neuraminidase inhibitors: antiviral action and mechanisms of resistance
2012
Pharmacokinetic Profile of Valganciclovir in Pediatric Transplant Recipients
2011
Management of Influenza in Households: A Prospective, Randomized Comparison of Oseltamivir Treatment With or Without Postexposure Prophylaxis
2004
Cytomegalovirus Serology and Replication Remain Associated With Solid Organ Graft Rejection and Graft Loss in the Era of Prophylactic Treatment
2014
Randomized Trial of Valganciclovir Versus Valacyclovir Prophylaxis for Prevention of Cytomegalovirus in Renal Transplantation
2014
24 Weeks of Valganciclovir Prophylaxis in Children After Renal Transplantation: A 4-Year Experience
2010
Pharmacokinetics and Safety of Valganciclovir in Pediatric Heart Transplant Recipients 4 Months of Age and Younger
2016
CMV-Specific T Cell Monitoring Offers Superior Risk Stratification of CMV-Seronegative Kidney Transplant Recipients of a CMV-Seropositive Donor
2017
Biological roles of glycans
2016 Standout
Antiviral agents active against influenza A viruses
2006
Current and future antiviral therapy of severe seasonal and avian influenza
2008
The cytokine storm of severe influenza and development of immunomodulatory therapy
2015 Standout
Anti-infective potential of natural products: How to develop a stronger in vitro ‘proof-of-concept’
2006 Standout
Influenza: old and new threats
2004
The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration
2009 Standout
CMV: Prevention, Diagnosis and Therapy
2013
Small-Molecule Library Screening by Docking with PyRx
2014 Standout
Delayed-Onset Cytomegalovirus Disease Coded During Hospital Readmission After Kidney Transplantation
2014
Computational design of trimeric influenza-neutralizing proteins targeting the hemagglutinin receptor binding site
2017 StandoutNobel
Glycotherapy: New Advances Inspire a Reemergence of Glycans in Medicine
2013 StandoutNobel
High Incidence of Anticytomegalovirus Drug Resistance Among D+R− Kidney Transplant Recipients Receiving Preemptive Therapy
2011
The Neuraminidase Inhibitor Oseltamivir Is Effective Against A/Anhui/1/2013 (H7N9) Influenza Virus in a Mouse Model of Acute Respiratory Distress Syndrome
2013
The potential impact of neuraminidase inhibitor resistant influenza
2008
The Third International Consensus Guidelines on the Management of Cytomegalovirus in Solid-organ Transplantation
2018 Standout
Strategies for mitigating an influenza pandemic
2006 StandoutNature
Long-Term Outcomes of Pre-emptive Valganciclovir Compared with Valacyclovir Prophylaxis for Prevention of Cytomegalovirus in Renal Transplantation
2012
Incidence and characterization of cytomegalovirus resistance mutations among pediatric solid organ transplant patients who received valganciclovir prophylaxis
2010
Is Cytomegalovirus Prophylaxis Dispensable in Patients Receiving an mTOR Inhibitor–Based Immunosuppression? A Systematic Review and Meta-Analysis
2012
Cytomegalovirus in Solid Organ Transplantation
2013
A Computationally Designed Hemagglutinin Stem-Binding Protein Provides In Vivo Protection from Influenza Independent of a Host Immune Response
2016 StandoutNobel
Antiviral activity of 3,4’-dihydroxyflavone on influenza a virus
2014
Impact of Antiviral Preventive Strategies on the Incidence and Outcomes of Cytomegalovirus Disease in Solid Organ Transplant Recipients
2013
State-of-the-Art Monitoring of Cytomegalovirus-Specific Cell-Mediated Immunity After Organ Transplant: A Primer for the Clinician
2012
Infection in Solid-Organ Transplant Recipients
2007 Standout
Preemptive therapy for cytomegalovirus based on real-time measurement of viral load in liver transplant recipients
2010
The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration
2009 Standout
Infections With Oseltamivir-Resistant Influenza A(H1N1) Virus in the United States
2009
An International Survey of Cytomegalovirus Management Practices in Lung Transplantation
2010
Iota-Carrageenan Is a Potent Inhibitor of Influenza A Virus Infection
2010
Leucomycin A3, a 16-membered macrolide antibiotic, inhibits influenza A virus infection and disease progression
2014 StandoutNobel
Quantitative Super-Resolution Microscopy of the Mammalian Glycocalyx
2019 StandoutNobel
Cytomegalovirus in Solid Organ Transplant Recipients
2009
Definitions of Cytomegalovirus Infection and Disease in Transplant Patients for Use in Clinical Trials: Table 1.
2016
Influenza Viruses Resistant to the Antiviral Drug Oseltamivir: Transmission Studies in Ferrets
2004
Evaluation of Low- Versus High-dose Valganciclovir for Prevention of Cytomegalovirus Disease in High-risk Renal Transplant Recipients
2015
The PRISMA Statement for Reporting Systematic Reviews and Meta-Analyses of Studies That Evaluate Health Care Interventions: Explanation and Elaboration
2009 Standout
Ionic-Liquid-Mediated Extraction and Separation Processes for Bioactive Compounds: Past, Present, and Future Trends
2017 Standout
Oseltamivir-Resistant Influenza Virus A (H1N1), Europe, 2007–08 Season
2009
Role of Secondary Prophylaxis With Valganciclovir in the Prevention of Recurrent Cytomegalovirus Disease in Solid Organ Transplant Recipients
2017
RapidIn VitroEvolution of Human Cytomegalovirus UL56 Mutations That Confer Letermovir Resistance
2015
Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2010.
2009 Standout
Comparative Glycomics Analysis of Influenza Hemagglutinin (H5N1) Produced in Vaccine Relevant Cell Platforms
2013
Cytomegalovirus Infections in Solid Organ Transplantation: A Review
2013
Pre-emptive treatment for cytomegalovirus viraemia to prevent cytomegalovirus disease in solid organ transplant recipients
2013
Molecular Mechanisms of the Anti-Obesity and Anti-Diabetic Properties of Flavonoids
2016 Standout
Improved Detection of Emerging Drug-Resistant Mutant Cytomegalovirus Subpopulations by Deep Sequencing
2014
Enhanced Expression of an α2,6-Linked Sialic Acid on MDCK Cells Improves Isolation of Human Influenza Viruses and Evaluation of Their Sensitivity to a Neuraminidase Inhibitor
2005
Increased risk of breakthrough infection among cytomegalovirus donor‐positive/recipient‐negative kidney transplant recipients receiving lower‐dose valganciclovir prophylaxis
2015
Lack of transmission of H5N1 avian–human reassortant influenza viruses in a ferret model
2006
Overexpression of the α-2,6-Sialyltransferase in MDCK Cells Increases Influenza Virus Sensitivity to Neuraminidase Inhibitors
2003
Carrageenan: a review
2013 Standout
Zanamivir-Resistant Influenza Viruses with a Novel Neuraminidase Mutation
2009
New algorithm for valganciclovir dosing in pediatric solid organ transplant recipients
2013
Resolution of Mild Ganciclovir-Resistant Cytomegalovirus Disease with Reduced-Dose Cidofovir and CMV-Hyperimmune Globulin
2014
Disease Tolerance as a Defense Strategy
2012 StandoutScience
Extended Valganciclovir Prophylaxis in D+/R− Kidney Transplant Recipients is Associated With Long-Term Reduction in Cytomegalovirus Disease: Two-Year Results of the IMPACT Study
2010
Synergistic Combinations of Favipiravir and Oseltamivir Against Wild-Type Pandemic and Oseltamivir-Resistant Influenza A Virus Infections in Mice
2013
The effect of sirolimus‐based immunosuppression vs. conventional prophylaxis therapy on cytomegalovirus infection after liver transplantation
2015
Antiviral Drug Resistance of Human Cytomegalovirus
2010
Valganciclovir dosing using area under the curve calculations in pediatric solid organ transplant recipients
2012
Valganciclovir versus valacyclovir prophylaxis for prevention of cytomegalovirus: an economic perspective
2015
The PRISMA Statement for Reporting Systematic Reviews and Meta-Analyses of Studies That Evaluate Health Care Interventions: Explanation and Elaboration
2009 Standout
Evidence of Synergistic Activity of Medicinal Plant Extracts against Neuraminidase Inhibitor Resistant Strains of Influenza Viruses
2014
Potential role of CC chemokine receptor 6 in prediction of late‐onset cytomegalovirus infection following solid organ transplant
2015
Human cytomegalovirus antiviral drug resistance in hematopoietic stem cell transplantation: current state of the art
2016
Avian Influenza A (H5N1) Infection in Humans
2005
A Comprehensive Review on Medicinal Plants as Antimicrobial Therapeutics: Potential Avenues of Biocompatible Drug Discovery
2019 Standout
Valganciclovir Prophylaxis against Cytomegalovirus Impairs Lymphocyte Proliferation and Activation in Renal Transplant Recipients
2011
Natural Products As Sources of New Drugs over the 30 Years from 1981 to 2010
2012 Standout
Clinical Utility of Molecular Surveillance for Cytomegalovirus After Antiviral Prophylaxis in High-Risk Solid Organ Transplant Recipients
2011
Antiviral medications for preventing cytomegalovirus disease in solid organ transplant recipients
2013
Neuraminidase Is Important for the Initiation of Influenza Virus Infection in Human Airway Epithelium
2004
Prevention and Control of Influenza: Recommendations of the Advisory Committee on Immunization Practices (ACIP)
2001 Standout
Works of J. Ives being referenced
The IMPACT Study: Valganciclovir Prophylaxis for until 200 Days Post-Transplant in High Risk Kidney Recipients Substantially Reduces the Incidence of CMV Disease.
2009
The Efficacy and Safety of 200 Days Valganciclovir Cytomegalovirus Prophylaxis in High‐Risk Kidney Transplant Recipients
2010
Pharmacokinetics of oral valganciclovir solution and intravenous ganciclovir in pediatric renal and liver transplant recipients
2009
Influenza virus carrying an R292K mutation in the neuraminidase gene is not transmitted in ferrets
2002
The H274Y mutation in the influenza A/H1N1 neuraminidase active site following oseltamivir phosphate treatment leave virus severely compromised both in vitro and in vivo
2002
Influenza virus carrying neuraminidase with reduced sensitivity to oseltamivir carboxylate has altered properties in vitro and is compromised for infectivity and replicative ability in vivo
2002
Phenotypic Evaluation of Previously Uncharacterized Cytomegalovirus DNA Polymerase Sequence Variants Detected in a Valganciclovir Treatment Trial
2013
Valganciclovir Dosing According to Body Surface Area and Renal Function in Pediatric Solid Organ Transplant Recipients
2009